This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use


Bionow members are welcome to submit PR items to this newsroom for all to see. An animated website user guide is available here which demonstrates how members can add news directly to the website after logging in. 

Whether currently a member or not, to keep in touch with all relevant news and information make sure you are registered to receive our newsletter.


Orla Protein Technologies awarded Innovate UK project to develop tools for use during checkpoint inhibitor drug development

27 April 2017

Orla Protein Technologies is proud to announce to have been chosen as a recipient of an Innovate UK grant for the development of proteins for use in the development of anti-cancer biopharmaceuticals. The project starting in April 2017 aims to engineer and develop five proteins for surface-application that will support development of drugs targeting immune checkpoint pathways.

> Read More


Blueberry Therapeutics commence Phase I/II clinical trial of lead product BB2603

25 April 2017

Blueberry Therapeutics are pleased to announce they have dosed the first patient in a Phase I/II clinical trial of BB2603 in fungal infection of the skin and nail following successful regulatory and ethics approvals.

> Read More


BPE strengthens new office with senior appointment

24 April 2017

BPE has strengthened its team in the North West with the appointment of Fiona Smith at its Daresbury base.

> Read More


Retrogenix receives its second prestigious Queen’s Award for Enterprise

21 April 2017

Retrogenix today announces that it has won a second Queen's Award for Enterprise in recognition of its outstanding growth in international trade. Serving a niche market in pharmaceutical development, Retrogenix's export sales now account for over 85% of the company's total turnover.

> Read More


Accelerating innovation with public and private investment

20 April 2017

As a UK business you can apply for a share of £8.5 million in grants and venture capital investment for early stage feasibility projects.

> Read More